Hirofumi Doi Selected Research

Type I Schindler Disease

1/2005	Three dimensional structural studies of alpha-N-acetylgalactosaminidase (alpha-NAGA) in alpha-NAGA deficiency (Kanzaki disease): different gene mutations cause peculiar structural changes in alpha-NAGAs resulting in different substrate specificities and clinical phenotypes.
1/2004	Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hirofumi Doi Research Topics

Disease

3	Neoplasms (Cancer) 10/2020 - 11/2013
2	Lymphatic Metastasis 10/2020 - 10/2020
2	Stomach Neoplasms (Stomach Cancer) 10/2020 - 10/2020
2	Fabry Disease (Fabry's Disease) 08/2005 - 01/2004
2	Type I Schindler Disease 01/2005 - 01/2004
2	Neuraminidase deficiency with beta-galactosidase deficiency 05/2004 - 01/2002
1	Chronic Renal Insufficiency 01/2021
1	Myocardial Infarction 01/2021
1	Ischemic Stroke 01/2021
1	Atherosclerosis 01/2021
1	Transient Ischemic Attack 01/2021
1	Diabetes Mellitus 01/2021
1	Ascites 10/2020
1	Hemorrhage 10/2020
1	Neoplasm Metastasis (Metastasis) 10/2020
1	Disease Progression 10/2020
1	Muscle Weakness 10/2020
1	Colonic Neoplasms (Colon Cancer) 01/2016
1	Body Weight (Weight, Body) 02/2011
1	Neuroaxonal Dystrophies (Neuroaxonal Dystrophy, Late Infantile) 01/2004
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2004
1	Nervous System Diseases (Neurological Disorders) 01/2004
1	Tay-Sachs Disease 01/2003
1	GM2 Gangliosidoses (GM2 Gangliosidosis) 01/2002
1	Mucolipidoses (Sialidosis) 01/2002

Drug/Important Bio-Agent (IBA)

2	Complementary DNA (cDNA)IBA 01/2021 - 01/2002
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
2	NivolumabIBA 10/2020 - 10/2020
2	EpiregulinIBA 01/2016 - 11/2013
2	Epidermal Growth Factor (EGF)IBA 01/2016 - 11/2013
2	alpha-N-Acetylgalactosaminidase (N-Acetyl-alpha-D-Galactosaminidase)IBA 01/2005 - 01/2004
2	EnzymesIBA 01/2004 - 01/2002
2	beta-N-AcetylhexosaminidasesIBA 01/2003 - 01/2002
1	Immunoglobulin G (IgG)IBA 01/2021
1	Recombinant ProteinsIBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	AntibodiesIBA 01/2021
1	AntigensIBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2020
1	Immune Checkpoint InhibitorsIBA 10/2020
1	RamucirumabIBA 10/2020
1	Pharmaceutical PreparationsIBA 10/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2020
1	Single-Chain AntibodiesIBA 01/2019
1	LigandsIBA 01/2016
1	ErbB Receptors (EGF Receptor)IBA 01/2016
1	Neutralizing AntibodiesIBA 01/2016
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2013
1	Messenger RNA (mRNA)IBA 02/2011
1	alpha-Galactosidase (Beano)IBA 08/2005
1	lactacystinIBA 05/2004
1	GlycoconjugatesIBA 01/2004
1	Tn antigenIBA 01/2004
1	Hexosaminidase A (Hex A)IBA 01/2003
1	5'-deoxy-5'-phosphonomethyladenosine phosphateIBA 01/2002
1	Cathepsin AIBA 01/2002
1	Neuraminidase (Sialidase)IBA 01/2002

Therapy/Procedure

3	Therapeutics 10/2020 - 01/2019
2	Drug Therapy (Chemotherapy) 10/2020 - 10/2020
1	Gastrectomy 10/2020
1	Immunotherapy 10/2020
1	Radiotherapy 10/2020
1	Precision Medicine 01/2019